LAES
SEALSQ Corp
Semiconductors
Market Cap$117M
5Y Perf.-72.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LAES vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$358K
5Y Perf.-33.9%
LAES vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LAES | XTLB |
|---|---|---|
| Industry | Semiconductors | Biotechnology |
| Market Cap | $117M | $358K |
| Revenue (TTM) | $35M | $451K |
| Net Income (TTM) | $-50M | $-1M |
| Gross Margin | 37.3% | 26.4% |
| Operating Margin | -136.9% | -481.6% |
| Total Debt | $9M | $138K |
| Cash & Equiv. | $85M | $371K |
LAES vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LAES
XTLB
| Stock | May 23 | May 26 | Return |
|---|---|---|---|
| SEALSQ Corp (LAES) | 100 | 27.7 | -72.3% |
| XTL Biopharmaceutic… (XTLB) | 100 | 66.1 | -33.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LAES vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LAES leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
LAES
SEALSQ Corp
The Long-Run Compounder
LAES carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -69.4% 10Y total return vs XTLB's -84.5%
- -63.5% revenue growth vs XTLB's -173.2%
- -141.3% margin vs XTLB's -227.7%
Best for: long-term compounding
XTLB
XTL Biopharmaceuticals Ltd.
The Income Pick
XTLB is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.71
- EPS growth 45.5%
- Lower volatility, beta 1.71, Low D/E 2.5%, current ratio 0.61x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LAES | -63.5% revenue growth vs XTLB's -173.2% |
| Quality / Margins | LAES | -141.3% margin vs XTLB's -227.7% |
| Stability / Safety | XTLB | Beta 1.71 vs LAES's 3.10, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | LAES | +41.9% vs XTLB's -43.6% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs LAES's -35.2%, ROIC -54.1% vs -165.0% |
LAES vs XTLB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
LAES vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTLBLAGGINGLAES
LAESSEALSQ Corp
1leads
XTLBXTL Biopharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs LAESMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LAES5/5
Valuation MetricsMultiples, price ratios, and targets
XTLB2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTLB5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LAES leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
LAES is the larger business by revenue, generating $35M annually — 78.4x XTLB's $451,000. Profitability is closely matched — net margins range from -141.3% (LAES) to -2.3% (XTLB).
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $35M | $451,000 |
| EBITDAEarnings before interest/tax | -$47M | -$1M |
| Net IncomeAfter-tax profit | -$50M | -$1M |
| Free Cash FlowCash after capex | -$31M | $0 |
| Gross MarginGross profit ÷ Revenue | +37.3% | +26.4% |
| Operating MarginEBIT ÷ Revenue | -136.9% | -4.8% |
| Net MarginNet income ÷ Revenue | -141.3% | -2.3% |
| FCF MarginFCF ÷ Revenue | -88.9% | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +75.0% | +20.0% |
LAES leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
XTLB leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $117M | $357,581 |
| Enterprise ValueMkt cap + debt − cash | $41M | $124,581 |
| Trailing P/EPrice ÷ TTM EPS | -4.88x | -0.34x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 10.66x | 0.79x |
| Price / BookPrice ÷ Book value/share | 1.50x | 0.07x |
| Price / FCFMarket cap ÷ FCF | — | — |
XTLB leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
XTLB leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-42 for LAES. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to LAES's 0.11x.
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -42.3% | -25.5% |
| ROA (TTM)Return on assets | -35.2% | -17.7% |
| ROICReturn on invested capital | -165.0% | -54.1% |
| ROCEReturn on capital employed | -34.0% | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.11x | 0.03x |
| Net DebtTotal debt minus cash | -$76M | -$233,000 |
| Cash & Equiv.Liquid assets | $85M | $371,000 |
| Total DebtShort + long-term debt | $9M | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | -13.04x | -13.31x |
XTLB leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — LAES and XTLB each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LAES five years ago would be worth $3,057 today (with dividends reinvested), compared to $2,369 for XTLB. Over the past 12 months, LAES leads with a +41.9% total return vs XTLB's -43.6%. The 3-year compound annual growth rate (CAGR) favors XTLB at -12.9% vs LAES's -32.6% — a key indicator of consistent wealth creation.
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -21.7% | +35.4% |
| 1-Year ReturnPast 12 months | +41.9% | -43.6% |
| 3-Year ReturnCumulative with dividends | -69.4% | -33.9% |
| 5-Year ReturnCumulative with dividends | -69.4% | -76.3% |
| 10-Year ReturnCumulative with dividends | -69.4% | -84.5% |
| CAGR (3Y)Annualised 3-year return | -32.6% | -12.9% |
Evenly matched — LAES and XTLB each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LAES and XTLB each lead in 1 of 2 comparable metrics.
Risk & Volatility
XTLB is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than LAES's 3.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LAES currently trades 38.1% from its 52-week high vs XTLB's 31.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.10x | 1.71x |
| 52-Week HighHighest price in past year | $8.71 | $10.28 |
| 52-Week LowLowest price in past year | $1.99 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +38.1% | +31.6% |
| RSI (14)Momentum oscillator 0–100 | 52.8 | 67.4 |
| Avg Volume (50D)Average daily shares traded | 10.3M | 2.4M |
Evenly matched — LAES and XTLB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | LAESSEALSQ Corp | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $7.50 | — |
| # AnalystsCovering analysts | 2 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XTLB leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). LAES leads in 1 (Income & Cash Flow). 2 tied.
Best OverallXTL Biopharmaceuticals Ltd. (XTLB)Leads 2 of 6 categories
Loading custom metrics...
LAES vs XTLB: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is LAES or XTLB a better buy right now?
Analysts rate SEALSQ Corp (LAES) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LAES or XTLB?
Over the past 5 years, SEALSQ Corp (LAES) delivered a total return of -69.
4%, compared to -76. 3% for XTL Biopharmaceuticals Ltd. (XTLB). Over 10 years, the gap is even starker: LAES returned -69. 4% versus XTLB's -84. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LAES or XTLB?
By beta (market sensitivity over 5 years), XTL Biopharmaceuticals Ltd.
(XTLB) is the lower-risk stock at 1. 71β versus SEALSQ Corp's 3. 10β — meaning LAES is approximately 82% more volatile than XTLB relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 11% for SEALSQ Corp — giving it more financial flexibility in a downturn.
04Which has better profit margins — LAES or XTLB?
SEALSQ Corp (LAES) is the more profitable company, earning -193.
1% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps -193. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LAES leads at -156. 6% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — LAES leads at 33. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — LAES or XTLB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is LAES or XTLB better for a retirement portfolio?
For long-horizon retirement investors, XTL Biopharmaceuticals Ltd.
(XTLB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. SEALSQ Corp (LAES) carries a higher beta of 3. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTLB: -84. 5%, LAES: -69. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between LAES and XTLB?
These companies operate in different sectors (LAES (Technology) and XTLB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.